# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001493152-20-007389
Filing Date
2020-04-29
Accepted
2020-04-29 17:24:02
Documents
10
Period of Report
2020-04-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | form8-k.htm | 8-K | 35100
2 |  | ex10-1.htm | EX-10.1 | 9508
3 |  | ex10-1_001.jpg | GRAPHIC | 108558
4 |  | ex10-1_002.jpg | GRAPHIC | 175848
5 |  | ex10-1_003.jpg | GRAPHIC | 183394
6 |  | ex10-1_004.jpg | GRAPHIC | 219204
7 |  | ex10-1_005.jpg | GRAPHIC | 161978
8 |  | ex10-1_006.jpg | GRAPHIC | 149175
9 |  | ex10-1_007.jpg | GRAPHIC | 161333
10 |  | ex10-1_008.jpg | GRAPHIC | 100677
| Complete submission text file | 0001493152-20-007389.txt |  | 1782466

Mailing Address 15 CUSHING IRVINE CA 92618
Business Address 15 CUSHING IRVINE CA 92618 949-409-7600
OncoCyte Corp (Filer) CIK: 0001642380 (see all company filings)

EIN.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37648 | Film No.: 20831827
SIC: 2835 In Vitro & In Vivo Diagnostic Substances